ALSO NOTED: Novartis cuts malaria drug price; India bars Cipla from exporting Tarceva copy;

> Novartis is slashing the public-sector price of its antimalarial med Coartem by 20 percent, to 80 cents from $1, to make the treatment more widely available. Report

> Delhi's High Court prohibited Cipla from exporting its generic version of the still-on-patent cancer treatment Tarceva, made by Roche. Report

> Pharmaceutical services firm AmerisourceBergen reported an 8 percent revenue hike to $17.85 billion and higher-than-expected earnings in its second quarter. Report

> Legal wrangling between the Centers for Medicare & Medicaid Services and pharmacy trade groups will delay a proposed federal rule lowering the reimbursement for dispensing generic drugs under Medicaid. Report

> Kyowa Pharmaceutical, the Japanese subsidiary of India's Lupin, won regulatory approval to sell 10 products in Japan, including risperidone (J&J's Risperdal) and amlodipine (Pfizer's Norvasc). Report

> After fears that UnitedHealth Group might take its pharmacy benefits management in-house, Medco managed to keep its contract with the insurance giant through 2012. Report

> Yesterday's FDA rejection of Genzyme's Myozyme underscores the challenges biosimilars face in the United States. Report

> In the first quarter of this year, venture capital investment dipped 5 percent to $7.1B, signaling that the current economic slump could have an impact on venture financing. However, there was still a dose of good news for biotech, raising $1.27 billion with 126 deals. Report

> Alpharma has withdrawn its NDA for Embeda, its extended-release painkiller. Report

> With about 40 drug development projects in the pipeline, Germany's Merck KGaA says it will spend about €1 billion ($1.58 billion) on drug research this year. Report

And Finally... The U.S. government is creating a $265 million research initiative that will develop new stem cell technology to re-grow the skin, limbs and muscles of soldiers injured in Iraq and Afghanistan. Report

Suggested Articles

Patients with epithelioid sarcoma previously had no targeted treatment options, but that'll change with Epizyme's approval for Tazverik.

With federal prosecutors laying waste to Insys' executive team, one big domino was still left to fall: Founder and former CEO John Kapoor.

Amgen buys out Astellas Japanese joint venture. Sun Piaoyang steps down as Hengrui chairman. Moderna-NIH and Inovio work on coronavirus vaccines.